Show simple item record

dc.contributor.authorIJzerman, MJen_US
dc.contributor.authorBerghuis, AMSen_US
dc.contributor.authorde Bono, JSen_US
dc.contributor.authorTerstappen, LWMMen_US
dc.coverage.spatialEnglanden_US
dc.date.accessioned2018-11-14T12:27:40Z
dc.date.issued2018-12en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/30052095en_US
dc.identifier.citationExpert Rev Pharmacoecon Outcomes Res, 2018, 18 (6), pp. 593 - 599en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2937
dc.identifier.eissn1744-8379en_US
dc.identifier.doi10.1080/14737167.2018.1505505en_US
dc.description.abstractINTRODUCTION: Liquid biopsies (LBs) are referred to as the sampling and analysis of non-solid tissue, primarily blood, as a diagnostic and monitoring tool for cancer. Because LBs are largely non-invasive, they are a less-costly alternative for serial analysis of tumor progression and heterogeneity to facilitate clinical management. Although a variety of tumor markers are proposed (e.g., free-circulating DNA), the clinical evidence for Circulating Tumor Cells (CTCs) is currently the most developed. Areas covered: This paper presents a health economic perspective of LBs in cancer management. We first briefly introduce the requirements in biomarker development and validation, illustrated for CTCs. Second, we discuss the state-of-art on the clinical utility of LBs in breast cancer in more detail. We conclude with a future perspective on the clinical use and reimbursement of LBs Expert commentary: A significant increase in clinical research on LBs can be observed and the results suggest a rapid change of cancer management. In addition to studies evaluating clinical utility of LBs, a smooth translation into clinical practice requires systematic assessment of the health economic benefits. This paper argues that (early stage) health economic research is required to facilitate its clinical use and to prioritize further evidence development.en_US
dc.format.extent593 - 599en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://www.rioxx.net/licenses/under-embargo-all-rights-reserveden_US
dc.subjectLiquid biopsiesen_US
dc.subjectbiomarkeren_US
dc.subjectcanceren_US
dc.subjectcirculating tumor cellsen_US
dc.subjectctDNAen_US
dc.subjectdiagnosticen_US
dc.subjecthealth economicsen_US
dc.subjectBiomarkers, Tumoren_US
dc.subjectBreast Neoplasmsen_US
dc.subjectDisease Progressionen_US
dc.subjectFemaleen_US
dc.subjectHumansen_US
dc.subjectLiquid Biopsyen_US
dc.subjectNeoplasmsen_US
dc.subjectNeoplastic Cells, Circulatingen_US
dc.subjectReimbursement Mechanismsen_US
dc.titleHealth economic impact of liquid biopsies in cancer management.en_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1080/14737167.2018.1505505en_US
rioxxterms.licenseref.startdate2018-12en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfExpert Rev Pharmacoecon Outcomes Resen_US
pubs.issue6en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.publication-statusPublisheden_US
pubs.volume18en_US
pubs.embargo.termsNot knownen_US
icr.researchteamProstate Cancer Targeted Therapy Groupen_US
dc.contributor.icrauthorDe Bono, Johannen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record